









Markets
/
Stocks
/
nasdaq-rckt
/

Rocket Pharmaceuticals Inc

RCKT

3.160USD

+0.160+5.33%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

341.94MMarket Cap

LossP/E TTM



Rocket Pharmaceuticals Inc

3.160

+0.160+5.33%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rocket Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Rocket Pharmaceuticals Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 143 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.71.In the medium term, the stock price is expected to remain stable.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rocket Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

143 / 392

Overall Ranking

288 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Rocket Pharmaceuticals Inc Highlights

StrengthsRisks

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -1.41, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 99.70M shares, decreasing 19.73% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 13.49K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.90.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

7.708

Target Price

+131.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Rocket Pharmaceuticals Inc is 5.45, ranking 363 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.45

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Rocket Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Rocket Pharmaceuticals Inc is 7.73, ranking 86 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.41, which is -36.91% below the recent high of -0.89 and -646.80% above the recent low of -10.52.

Score

Industry at a Glance

Previous score

7.73

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 143/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Rocket Pharmaceuticals Inc is 7.07, ranking 310 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 16.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.07

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

7.708

Target Price

+131.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Rocket Pharmaceuticals Inc

RCKT

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Rocket Pharmaceuticals Inc is 5.53, ranking 311 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.77 and the support level at 2.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.30

Change

0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.147

Sell

RSI(14)

37.533

Neutral

STOCH(KDJ)(9,3,3)

14.560

Oversold

ATR(14)

0.211

High Vlolatility

CCI(14)

-163.600

Sell

Williams %R

83.316

Oversold

TRIX(12,20)

-0.198

Sell

StochRSI(14)

51.191

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.286

Sell

MA10

3.432

Sell

MA20

3.579

Sell

MA50

3.487

Sell

MA100

3.441

Sell

MA200

3.686

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Rocket Pharmaceuticals Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 92.13%, representing a quarter-over-quarter increase of 2.61%. The largest institutional shareholder is The Vanguard, holding a total of 8.54M shares, representing 7.90% of shares outstanding, with 28.82% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RTW Investments L.P.

17.69M

The Vanguard Group, Inc.

Star Investors

6.89M

+12.97%

Maverick Capital, Ltd.

Star Investors

8.47M

+1.25%

BlackRock Institutional Trust Company, N.A.

6.02M

-5.16%

MPM BioImpact LLC

3.90M

+0.01%

Suvretta Capital Management, LLC

3.84M

-7.24%

Millennium Management LLC

3.57M

+52.01%

Two Sigma Investments, LP

3.41M

+5.48%

Monaco asset management S.A.M.

2.89M

+538.80%

Morgan Stanley & Co. LLC

2.66M

+31.69%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Rocket Pharmaceuticals Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.